Cargando…

The incidence of gastrointestinal adverse events in patients with advanced non-small cell lung cancer (NSCLC) treated with PD-1 inhibitors: a meta-analysis

BACKGROUND: We conducted a meta-analysis to evaluates the incidence of the gastrointestinal (GI) adverse events with the use of PD-1 inhibitors among patients with advanced non-small cell lung cancer (NSCLC). METHODS: The PICOs (participants, intervention, comparison, and outcomes) elements were use...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huo, Geng-Wei, Zhu, Fu-Yi, Zuo, Ran, Song, Ying, Chen, Wei-Dong, Chen, Wen-Ming, Zhang, Hong-Mei, Jia, Sha-Sha, Chen, Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798015/ https://www.ncbi.nlm.nih.gov/pubmed/35116644 http://dx.doi.org/10.21037/tcr-21-125

Ejemplares similares

Immune-Related Adverse Events Associated With Outcomes in Patients With NSCLC Treated With Anti-PD-1 Inhibitors: A Systematic Review and Meta-Analysis
por: Zhao, Zhe, et al.
Publicado: (2021)

Therapeutic and Systemic Adverse Events of Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 axis for Clinical Management of NSCLC
por: Chen, Jing, et al.
Publicado: (2021)

Ocular adverse events in PD-1 and PD-L1 inhibitors
por: Young, LeAnne, et al.
Publicado: (2021)

Effect of antibiotic use on the efficacy of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer: A meta-analysis
por: Huo, Geng-wei, et al.
Publicado: (2021)

Association between Early Immune-Related Adverse Events and Survival in Patients Treated with PD-1/PD-L1 Inhibitors
por: Zhang, You-Cheng, et al.
Publicado: (2023)

Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors
por: Yoon, Jee Hee, et al.
Publicado: (2021)

Meta-analysis of incidence and risk of severe adverse events and fatal adverse events with crizotinib monotherapy in patients with ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)

Nintedanib in advanced NSCLC: management of adverse events
por: Lemmens, Liesbeth
Publicado: (2016)

Cutaneous adverse events in patients treated with PD-1/PD-L1 checkpoint inhibitors and their association with survival: a systematic review and meta-analysis
por: Zhao, Fangmin, et al.
Publicado: (2022)

Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival
por: Xie, Peiyi, et al.
Publicado: (2021)

Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors
por: Chen, Jianing, et al.
Publicado: (2022)

ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors
por: Nie, Wei, et al.
Publicado: (2022)

Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors
por: Peng, Lihong, et al.
Publicado: (2020)

Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors
por: Wang, Zheng-Hang, et al.
Publicado: (2018)

Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy
por: Rajha, Eva, et al.
Publicado: (2019)

A real-world retrospective study of incidence and associated factors of endocrine adverse events related to PD-1/PD-L1 inhibitors
por: Wang, Zhiyi, et al.
Publicado: (2023)

Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy
por: Sayer, Michael R., et al.
Publicado: (2023)

Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
por: Zhou, Yanting, et al.
Publicado: (2023)

A model‐based meta‐analysis of immune‐related adverse events during immune checkpoint inhibitors treatment for NSCLC
por: Zhang, Renwei, et al.
Publicado: (2022)

Intestinal Microbiome Associated With Immune-Related Adverse Events for Patients Treated With Anti-PD-1 Inhibitors, a Real-World Study
por: Liu, Wenhui, et al.
Publicado: (2021)

Gastrointestinal adverse events of immunotherapy
por: Cappello, Giovanni, et al.
Publicado: (2021)

Incidence and characteristics of adverse drug reactions in a cohort of patients treated with PD-1/PD-L1 inhibitors in real-world practice
por: Sabaté Gallego, Mònica, et al.
Publicado: (2022)

Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors
por: Griewing, Luisa Maria, et al.
Publicado: (2021)

Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management
por: Shivaji, Uday N., et al.
Publicado: (2019)

Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade
por: Wang, Shuhang, et al.
Publicado: (2022)

Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors
por: Zhang, Yifan, et al.
Publicado: (2023)

Progressive Pleural Effusion as an Immune-Related Adverse Event in NSCLC: A Case Report
por: Shen, Chia-I, et al.
Publicado: (2021)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
por: Wang, Yuanyuan, et al.
Publicado: (2021)

Incidence of Bone Metastases and Skeletal-Related Events in Patients With EGFR-Mutated NSCLC Treated With Osimertinib
por: Brouns, Anita J.W. M., et al.
Publicado: (2023)

Tumor response assessment by measuring the single largest lesion per organ in advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitor
por: He, Li-Na, et al.
Publicado: (2023)

High incidence and reversible bradycardia events following alectinib initiation
por: Yuan, Dongqi, et al.
Publicado: (2022)

Patterns of response in metastatic NSCLC during PD‐1 or PD‐L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria
por: Liang, Hongge, et al.
Publicado: (2020)

Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters
por: Castello, Angelo, et al.
Publicado: (2020)

Adverse events of different PD-1 inhibitors in lung cancer patients: a real-world study
por: Zheng, Xiaowei, et al.
Publicado: (2022)

Meta-Analysis of Gastrointestinal Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
por: Mohanavelu, Prahathishree, et al.
Publicado: (2021)

Radiomics combined with transcriptomics to predict response to immunotherapy from patients treated with PD-1/PD-L1 inhibitors for advanced NSCLC
por: Bouhamama, Amine, et al.
Publicado: (2023)

Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor
por: Bai, Xin, et al.
Publicado: (2021)

Immune‐Related Adverse Events in the Setting of PD‐1/L1 Inhibitor Combination Therapy
por: Zubiri, Leyre, et al.
Publicado: (2019)

Prognostic value of inflammatory and nutritional indexes among advanced NSCLC patients receiving PD‐1 inhibitor therapy
por: Fang, Qiyu, et al.
Publicado: (2022)

Pleural or pericardial metastasis: A significant factor affecting efficacy and adverse events in lung cancer patients treated with PD‐1/PD‐L1 inhibitors
por: Kang, Da Hyun, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_u9pqncdhvqph8253hbol8ovd61